Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R. & Abel, E. D. Cardiac vitality metabolism in coronary heart failure. Circ. Res. 128, 1487–1513 (2021).
Heiden, M. G. V., Cantley, L. C. & Thompson, C. B. Understanding the Warburg impact: the metabolic necessities of cell proliferation. Science 324, 1029–1033 (2009).
Bergers, G. & Fendt, S. M. The metabolism of most cancers cells throughout metastasis. Nat. Rev. Most cancers 21, 162–180 (2021).
Kanarek, N., Petrova, B. & Sabatini, D. M. Dietary modifications for enhanced most cancers remedy. Nature 579, 507–517 (2020).
Mossmann, D., Park, S. & Corridor, M. N. mTOR signalling and mobile metabolism are mutual determinants in most cancers. Nat. Rev. Most cancers 18, 744–757 (2018).
Liu, G. Y. & Sabatini, D. M. mTOR on the nexus of diet, progress, ageing and illness. Nat. Rev. Mol. Cell Biol. 21, 183–203 (2020).
Li, X. Y. et al. Navigating metabolic pathways to boost antitumour immunity and immunotherapy. Nat. Rev. Clin. Oncol. 16, 425–441 (2019).
Colegio, O. R. et al. Purposeful polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559–563 (2014).
Zappasodi, R. et al. CTLA-4 blockade drives lack of Treg stability in glycolysis-low tumours. Nature 591, 652–658 (2021).
Calvo, M. S. & Lamberg-Allardt, C. J. Phosphorus. Adv. Nutr. 6, 860–862 (2015).
Boyer, P. D., Falcone, A. B. & Harrison, W. H. Reversal and mechanism of oxidative phosphorylation. Nature 174, 401–402 (1954).
Ubersax, J. A. & Ferrell, J. E. Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol. 8, 530–541 (2007).
Gonzalez, P. S. et al. Mannose impairs tumour progress and enhances chemotherapy. Nature 563, 719–723 (2018).
Music, L. T. et al. Proto-oncogene Src hyperlinks lipogenesis by way of lipin-1 to breast most cancers malignancy. Nat. Commun. 11, 5842 (2020).
Gui, R. J., Jin, H., Wang, Z. H. & Li, J. H. Black phosphorus quantum dots: synthesis, properties, functionalized modification and purposes. Chem. Soc. Rev. 47, 6795–6823 (2018).
Li, L. Okay. et al. Black phosphorus field-effect transistors. Nat. Nanotechnol. 9, 372–377 (2014).
Zhou, W. H. et al. Black phosphorus: bioactive nanomaterials with inherent and selective chemotherapeutic results. Angew. Chem. Int. Ed. 58, 769–774 (2019).
Zhang, X. G. et al. A focusing on black phosphorus nanoparticle primarily based immune cells nano-regulator for photodynamic/photothermal and photo-immunotherapy. Bioact. Mater. 6, 472–489 (2021).
Chen, W. S. et al. Black phosphorus nanosheet-based drug supply system for synergistic photodynamic/photothermal/chemotherapy of most cancers. Adv. Mater. 29, 1603864 (2017).
Liu, J. T. et al. Twin-triggered oxygen self-supply black phosphorus nanosystem for enhanced photodynamic remedy. Biomaterials 172, 83–91 (2018).
Shao, X. M. et al. Intrinsic bioactivity of black phosphorus nanomaterials on mitotic centrosome destabilization by way of suppression of PLK1 kinase. Nat. Nanotechnol. 16, 1150–1160 (2021).
Cheung, E. C. & Vousden, Okay. H. The function of ROS in tumour growth and development. Nat. Rev. Most cancers 22, 280–297 (2022).
Bian, S. Q. et al. The self-crosslinking good hyaluronic acid hydrogels as injectable three-dimensional scaffolds for cells tradition. Colloids Surf. B Biointerfaces 1, 392–402 (2016).
Hou, J. et al. Treating acute kidney harm with antioxidative black phosphorus nanosheets. Nano Lett. 20, 1447–1454 (2020).
Huang, H. et al. Black phosphorus: a two-dimensional reductant for in situ nanofabrication. npj 2D Mater. Appl. 1, 20 (2017).
Jin, H. J. et al. EGFR activation limits the response of liver most cancers to lenvatinib. Nature 595, 730–734 (2021).
Downward, J. Focusing on RAS signalling pathways in most cancers remedy. Nat. Rev. Most cancers 3, 11–22 (2003).
Hoxhaj, G. & Manning, B. D. The PI3K-AKT community on the interface of oncogenic signalling and most cancers metabolism. Nat. Rev. Most cancers 20, 74–88 (2020).
Gremke, N. et al. mTOR-mediated most cancers drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nat. Commun. 11, 4684 (2020).
Wu, Y. Q. et al. ARIH1 signaling promotes anti-tumor immunity by focusing on PD-L1 for proteasomal degradation. Nat. Commun. 12, 2346 (2021).
Ding, X. C. et al. The connection between expression of PD-L1 and HIF-1α in glioma cells beneath hypoxia. J. Hematol. Oncol. 14, 92 (2021).
Reda, M. et al. Growth of a nanoparticle-based immunotherapy focusing on PD-L1 and PLK1 for lung most cancers therapy. Nat. Commun. 13, 4261 (2022).
Bailey, M. H. et al. Complete characterization of most cancers driver genes and mutations. Cell 173, 371–385 (2018).
Chen, G. et al. Exosomal PD-L1 contributes to immunosuppression and is related to anti-PD-1 response. Nature 560, 382–386 (2018).
Dror, S. et al. Melanoma miRNA trafficking controls tumour major area of interest formation. Nat. Cell Biol. 18, 1006–1017 (2016).
Poggio, M. et al. PD-L1 suppression of exosomal PD-L1 induces systemic anti-tumor immunity and reminiscence. Cell 177, 414–427 (2019).
Shen, Y. Y. et al. Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation. Nat. Commun. 13, 3419 (2022).
Golan, T. et al. Interactions of melanoma cells with distal keratinocytes set off metastasis by way of notch signaling inhibition of MITF. Mol. Cell 59, 664–676 (2015).
Lewis, S. M., Williams, A. & Eisenbarth, S. C. Construction and performance of the immune system within the spleen. Sci. Immunol. 4, eaau6085 (2019).
Belz, G. T., Bedoui, S., Kupresanin, F., Carbone, F. R. & Heath, W. R. Minimal activation of reminiscence CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat. Immunol. 8, 1060–1066 (2007).
Im, S. J. et al. Defining CD8+ T cells that present the proliferative burst after PD-1 remedy. Nature 537, 417–421 (2016).
Jung, Y. W., Kim, H. G., Perry, C. J. & Kaech, S. M. CCR7 expression alters reminiscence CD8 T-cell homeostasis by regulating occupancy in IL-7-and IL-15-dependent niches. Proc. Natl Acad. Sci. USA 113, 8278–8283 (2016).
Gilchrist, J. J. et al. Pure killer cells exhibit distinct eQTL and transcriptome-wide illness associations, highlighting their function in autoimmunity. Nat. Commun. 13, 4073 (2022).
Wculek, S. Okay. et al. Dendritic cells in most cancers immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).
Olmeda, D. et al. Entire-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine. Nature 546, 676–680 (2017).
Owens, B. Melanoma. Nature 515, S109 (2014).
Robert, C. et al. Pembrolizumab versus ipilimumab in superior melanoma (KEYNOTE-006): post-hoc 5-year outcomes from an open-label, multicentre, randomised, managed, section 3 research. Lancet Oncol. 20, 1239–1251 (2019).
Zhang, T. et al. Degradation chemistry and stabilization of exfoliated few-layer black phosphorus in water. J. Am. Chem. Soc. 140, 7561–7567 (2018).
Liao, Z., Chua, D. & Tan, N. S. Reactive oxygen species: a unstable driver of subject cancerization and metastasis. Mol. Most cancers 18, 65 (2019).
Boese, A. C. & Kang, S. Mitochondrial metabolism-mediated redox regulation in most cancers development. Redox Biol. 42, 101870 (2021).
Zhou, C. F. et al. Nynrin preserves hematopoietic stem cell operate by inhibiting the mitochondrial permeability transition pore opening. Cell Stem Cell 31, 1359–1375 (2024).
Hou, D. et al. Cationic antimicrobial peptide NRC-03 induces oral squamous cell carcinoma cell apoptosis by way of CypD-mPTP axis-mediated mitochondrial oxidative stress. Redox Biol. 54, 102355 (2022).
Carne Trecesson, S. et al. BCL-XL instantly modulates RAS signalling to favour most cancers cell stemness. Nat. Commun. 8, 1123 (2017).
KEGG pathway: map05235. https://www.genome.jp/entry/map05235 (2019).
Liu, Y. et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 33, 1221–1233 (2021).
Reinfeld, B. I., Rathmell, W. Okay., Kim, T. Okay. & Rathmell, J. C. The therapeutic implications of immunosuppressive tumor cardio glycolysis. Cell Mol. Immunol. 19, 46–58 (2022).
Watson, M. J. et al. Metabolic assist of tumour-infiltrating regulatory T cells by lactic acid. Nature 591, 645–651 (2021).
Sanmamed, M. F. & Chen, L. A paradigm shift in most cancers immunotherapy: from enhancement to normalization. Cell 175, 313–326 (2018).
Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for most cancers remedy. Nat. Rev. Clin. Oncol. 19, 237–253 (2022).
Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6, 114057 (2020).